期刊
CURRENT ONCOLOGY REPORTS
卷 22, 期 4, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-020-0893-0
关键词
Chronic lymphocytic leukaemia; Chemoimmunotherapy; Ibrutinib; Venetoclax; Future
类别
资金
- National institute for Health Research (NIHR) Academic Clinical Fellowship award
- Bloodwise, UK
Purpose of Review Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the treatment approaches used for these different subgroups. Recent Findings Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will be translated into durable remissions. Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the majority of patients, early after diagnosis and with curative intent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据